431 related articles for article (PubMed ID: 37322293)
1. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
4.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
Syed YY
Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
8. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
[TBL] [Abstract][Full Text] [Related]
9. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
10. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
[TBL] [Abstract][Full Text] [Related]
11. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
[TBL] [Abstract][Full Text] [Related]
12. Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study.
Bassetti M; Ariyasu M; Binkowitz B; Nagata TD; Echols RM; Matsunaga Y; Toyoizumi K; Doi Y
Infect Drug Resist; 2019; 12():3607-3623. PubMed ID: 31819544
[TBL] [Abstract][Full Text] [Related]
13. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol (Fetroja) as a Treatment for Hospital-Acquired Pneumonia.
Plaisance CJ; Borne GE; Daniel CP; Wagner MJ; Shelvan A; Mathew J; Ahmadzadeh S; Paladini A; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2024 Jan; 16(1):e52230. PubMed ID: 38352089
[TBL] [Abstract][Full Text] [Related]
17. Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.
Parsels KA; Mastro KA; Steele JM; Thomas SJ; Kufel WD
J Antimicrob Chemother; 2021 May; 76(6):1379-1391. PubMed ID: 33532823
[TBL] [Abstract][Full Text] [Related]
18. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Ong'uti S; Czech M; Robilotti E; Holubar M
Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
[TBL] [Abstract][Full Text] [Related]
19. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
Jorda A; Zeitlinger M
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
